Last reviewed · How we verify
profile of CSF biomarkers of AD
profile of CSF biomarkers of AD is a Biologic drug developed by Hospices Civils de Lyon. It is currently in Phase 1 development.
At a glance
| Generic name | profile of CSF biomarkers of AD |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- VR Pupillometry in Cognitive Impairment
- Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease (PHASE4)
- Predictive Value of Biomarkers of the Alzheimer's Disease (AD) in Elderly Patients With New-onset Epilepsy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- profile of CSF biomarkers of AD CI brief — competitive landscape report
- profile of CSF biomarkers of AD updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about profile of CSF biomarkers of AD
What is profile of CSF biomarkers of AD?
profile of CSF biomarkers of AD is a Biologic drug developed by Hospices Civils de Lyon.
Who makes profile of CSF biomarkers of AD?
profile of CSF biomarkers of AD is developed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).
What development phase is profile of CSF biomarkers of AD in?
profile of CSF biomarkers of AD is in Phase 1.
Related
- Manufacturer: Hospices Civils de Lyon — full pipeline